MDM2 and cancer: One of the strategies tested in tumors that retain wild-type p53 is hindering the MDM2/p53 interaction and improving p53 function. Through the restoration of the p53-mediated tumor suppression pathway, cancer cell growth arrest and apoptosis were induced while generating minimal cytotoxicity and side effects, which has led to the discovery of Nutlin, a precise inhibitor of the p53/MDM2 interaction.